Publications

Publications

Filter Results: (14) Arrow Down

Show Results For

Page 1 of 14 Results
  • November 2012
  • Supplement

Amylin Pharmaceuticals (B)

By: Richard G. Hamermesh and Carin-Isabel Knoop
Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details
Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States
Related
  • November 2008
  • Case

Adnexus Therapeutics, Inc.: Considering the Exit

By: Vicki L. Sato and Rachel Gordon
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry
Related
  • November 2020
  • Supplement

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • November 2020
  • Case

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • November 2020
  • Teaching Note

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
Keywords: Mergers and Acquisitions; Valuation; Value; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • 14 Mar 2014
  • HBS Seminar

Jeremy M. Levin, former President and CEO, Teva Pharmaceutical Industries

  • Web

Great American Business Leaders of the 20th Century - Leadership

Geffen Geffen Records, 1984–1989 Richard L. Gelb Bristol-Myers Squibb Company, 1972–1994 Harold S. Geneen International Telephone and Telegraph, 1959–1977 William W. George Medtronic, 1991–2000 Daniel F.... View Details
  • Web

Recruiting Partners - Health Care

Brighton Health Group Bristol-Myers Squibb Broadview Ventures Business Talent Group C C. R. Bard, Inc. C1 Consulting, LLC Caladrius Biosciences California Family Health Council Call9 Cambia Health Solutions... View Details

    Richard L. Gelb

    Gelb orchestrated Bristol-Myers' successful acquisition of Squibb creating the second largest pharmaceutical company in the world. In diversifying Bristol-Myers from a personal care company to pharmaceutical... View Details
    Keywords: Healthcare
    • 01 Jun 2015
    • News

    The Military and the MBA: Chris Howard (MBA 2003)

    the military, I took those lessons with me to Bristol-Myers Squibb and then to HBS. We were in class when 9/11 happened. I was a reservist. A few weeks later I got a call saying I was being returned to... View Details
    Keywords: National Security and International Affairs; Government
    • 01 Feb 1999
    • News

    Classmates Rally to Help Family Stricken with Rare Disease

    diagnosed, also has the disease. Crowley, who is a director at Bristol-Myers Squibb in Princeton, New Jersey, recalls how he learned that his children were sick. "When Megan was around five months old, we... View Details
    • 25 Feb 2002
    • Research & Ideas

    MNCs in Asia: Investing in the Future

    difficult," responded Anthony C. Hooper, president of Bristol-Myers Squibb Intercontinental Region, recalling how last-minute pricing interference by the Chinese government wreaked havoc with the... View Details
    Keywords: by Julia Hanna
    • 19 May 2009
    • First Look

    First Look: May 19, 2009

    Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. Purchase this case: http://hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=609015 Arcadia... View Details
    Keywords: Martha Lagace
    • 15 Jan 2013
    • First Look

    First Look: January 15

    Amgen, Inc. In 2012, Amylin was acquired by Bristol-Myers Squibb for $5.3 billion. Purchase this case:http://hbr.org/search/813091-PDF-ENG Rock Health Higgins, Robert F., and Ian McKowan CornellHarvard... View Details
    Keywords: Sean Silverthorne